#United States #New York #Class Action #ImmunityBio #IBRX

Class Action Lawsuit Filed Against ImmunityBio for Securities Fraud: What Investors Should Know

Overview of the ImmunityBio Class Action Lawsuit

On April 1, 2026, Levi & Korsinsky, LLP announced that a class action lawsuit had been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). This lawsuit is in response to significant losses incurred by investors who purchased securities between January 19, 2026, and March 24, 2026. During this period, ImmunityBio's stock plummeted by approximately 21%, translating to a loss of $1.98 per share, following revelations from the FDA that the company's promotional communications were misleading.

Recruitment of Lead Plaintiff

Investors aiming to lead the class action must act quickly, as the deadline to file a motion is May 26, 2026. Under the Private Securities Litigation Reform Act (PSLRA) of 1995, any investor who suffered losses during the designated period qualifies to apply for lead plaintiff status. The court will evaluate applications based on the financial interests of applicants, thereby selecting a representative with the most significant stakes in the outcome of the litigation.

Key Dates and Processes

- Important Date: May 26, 2026
- Interested investors must file motions by this date to be considered as lead plaintiffs.
- The appointed lead plaintiff will have the authority to select a law firm representing all class members and will oversee the litigation strategy.

Insights on Class Membership

All investors who purchased IBRX shares within the stated timeframe, regardless of their lead plaintiff status, are automatically included in any recovery that is achieved. Importantly, there are no minimum loss requirements to become a class member. Individuals interested in pursuing lead plaintiff status or participating in the case should gather relevant brokerage records, including purchase dates and transaction details, and contact Levi & Korsinsky for assistance.